» Articles » PMID: 33253684

Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy

Overview
Specialty Gastroenterology
Date 2020 Nov 30
PMID 33253684
Citations 167
Authors
Affiliations
Soon will be listed here.
Abstract

The commensal microbiota has been implicated in the regulation of a diverse array of physiological processes, both within the gastrointestinal tract and at distant tissue sites. Cancer is no exception, and distinct aspects of the microbiota have been reported to have either pro- or anti-tumor effects. The functional role of the microbiota in regulating not only mucosal but also systemic immune responses has led to investigations into the impact on cancer immunotherapies, particularly with agents targeting the immunologic checkpoints PD-1 and CTLA-4. Microbial sequencing and reconstitution of germ-free mice have indicated both positive and negative regulatory bacteria likely exist, which either promote or interfere with immunotherapy efficacy. These collective findings have led to the development of clinical trials pursuing microbiome-based therapeutic interventions, with the hope of expanding immunotherapy efficacy. This review summarizes recent knowledge about the relationship between the host microbiota and cancer and anti-tumor immune response, with implications for cancer therapy.

Citing Articles

Bacterial-Mediated In Situ Engineering of Tumour-Associated Macrophages for Cancer Immunotherapy.

Kuhl G, Tangney M Cancers (Basel). 2025; 17(5).

PMID: 40075571 PMC: 11899205. DOI: 10.3390/cancers17050723.


Leveraging microbiome signatures to predict tumor immune microenvironment and prognosis of patients with endometrial carcinoma.

Yang Y, Meng Y, Xu Z, Zhang Q, Li M, Kong F Discov Oncol. 2025; 16(1):299.

PMID: 40069468 PMC: 11896907. DOI: 10.1007/s12672-025-02038-9.


Role of tertiary lymphoid structures and B cells in clinical immunotherapy of gastric cancer.

Chen W, Zhang L, Gao M, Zhang N, Wang R, Liu Y Front Immunol. 2025; 15():1519034.

PMID: 39840050 PMC: 11747648. DOI: 10.3389/fimmu.2024.1519034.


Exploring the effects of gut microbiota on cholangiocarcinoma progression by patient-derived organoids.

Lederer A, Gorrissen N, Nguyen T, Kreutz C, Rasel H, Bartsch F J Transl Med. 2025; 23(1):34.

PMID: 39789543 PMC: 11716211. DOI: 10.1186/s12967-024-06012-x.


Insights into the Relationship Between the Gut Microbiome and Immune Checkpoint Inhibitors in Solid Tumors.

Ciernikova S, Sevcikova A, Novisedlakova M, Mego M Cancers (Basel). 2025; 16(24.

PMID: 39766170 PMC: 11674129. DOI: 10.3390/cancers16244271.


References
1.
Allegretti J, Kelly C, Grinspan A, Mullish B, Kassam Z, Fischer M . Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection. Gastroenterology. 2020; 159(5):1982-1984. DOI: 10.1053/j.gastro.2020.07.045. View

2.
Iida N, Dzutsev A, Stewart C, Smith L, Bouladoux N, Weingarten R . Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013; 342(6161):967-70. PMC: 6709532. DOI: 10.1126/science.1240527. View

3.
Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

4.
Lagier J, Khelaifia S, Alou M, Ndongo S, Dione N, Hugon P . Culture of previously uncultured members of the human gut microbiota by culturomics. Nat Microbiol. 2016; 1:16203. DOI: 10.1038/nmicrobiol.2016.203. View

5.
Pushalkar S, Hundeyin M, Daley D, Zambirinis C, Kurz E, Mishra A . The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discov. 2018; 8(4):403-416. PMC: 6225783. DOI: 10.1158/2159-8290.CD-17-1134. View